Trial Profile
A Phase I Dose Escalation Trial of WT1-Specific T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs WT1 protein-specific T-cell therapy Atara/MSKCC (Primary)
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 01 Mar 2021 Status changed from active, no longer recruiting to completed.
- 19 Jan 2021 Planned End Date changed from 1 Feb 2021 to 1 Feb 2022.
- 19 Jan 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2022.